Business conduct
Novartis is committed to sustainable performance built on a solid foundation of ethical values at all levels of our business.
We have received recognition from key indices and rankings because we work to make this commitment a reality. In 2009, Novartis was:
- Named one of the leaders in the pharmaceutical sector in the Dow Jones Sustainability Index
- Ranked among the most respected companies in the world by Barron's magazine
Learn more on our corporate citizenship website
R&D
Healthcare companies invested more than USD 65 billion in research and development in 2009, providing a major contribution to health research. During 2009, Novartis invested significantly in research and development: USD 7.5 billion. This is one of the highest figures in the industry relative to sales (17 percent).
Research & development in USD billion (% of net sales)
Novartis research and development efforts are driven by a commitment to health and well-being. Working at the frontier of science and technology means our activities may involve ethical issues, including animal welfare or stem-cell research. We recognize the importance of an informed debate about these issues and welcome the opportunity to engage in constructive dialogue.
Making long-term investments in better health
On average, only one in 10 000 originally synthesized compounds will clear all regulatory hurdles and become a commercially available drug. The research and development process for bringing a new drug to market can take 10 to 12 years to complete and cost up to USD 1.7 billion.
Ethical marketing
Novartis provides accurate information to healthcare professionals and consumers.
Citizenship in action
The Regional Psychosocial Support Initiative brings hope to AIDS orphans in Africa.
Corporate governance
We are fully committed to good corporate governance.
